Skip to content

Study · Measured the body's own peptide · 2012

2 results

MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer.

Grüner BM, Hahne H, Mazur PK, Trajkovic-Arsic M, Maier S, Esposito I, Kalideris E, Michalski CW, Kleeff J, Rauser S, Schmid RM, Küster B, Walch A, Siveke JT

PloS one26 Jun 2012Cited by 43 (Europe PMC)

PMID22761793 (opens in a new tab)PMCIDPMC3383687 (opens in a new tab)DOI10.1371/journal.pone.0039424 (opens in a new tab)PepBankPUB-22761793
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

The identification of new biomarkers for preneoplastic pancreatic lesions (PanINs, IPMNs) and early pancreatic ductal adenocarcinoma (PDAC) is crucial due to the diseases high mortality rate upon late detection. To address this task we used the novel technique of matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) on genetically engineered mouse models (GEM) of pancreatic cancer. Various GEM were analyzed with MALDI IMS to investigate the peptide/protein-expression pattern of precursor lesions in comparison to normal pancreas and PDAC with cellular resolution. Statistical analysis revealed several discriminative m/z-species between normal and diseased tissue. Intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) could be distinguished from normal pancreatic tissue and PDAC by 26 significant m/z-species. Among these m/z-species, we identified Albumin and Thymosin-beta 4 by liquid chromatography and tandem mass spectrometry (LC-MS/MS), which were further validated by immunohistochemistry, western blot, quantitative RT-PCR and ELISA in both murine and human tissue. Thymosin-beta 4 was found significantly increased in sera of mice with PanIN lesions. Upregulated PanIN expression of Albumin was accompanied by increased expression of liver-restricted genes suggesting a hepatic transdifferentiation program of preneoplastic cells. In conclusion we show that GEM of endogenous PDAC are a suitable model system for MALDI-IMS and subsequent LC-MS/MS analysis, allowing in situ analysis of small precursor lesions and identification of differentially expressed peptides and proteins.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In genetically engineered mouse models of pancreatic cancer, Tβ4 was identified among 26 m/z species that distinguished PanIN and IPMN from normal pancreas and PDAC.

    In plain wordsIn mice, the body's own thymosin β4 was one of the molecules that set early pancreatic lesions apart from normal tissue.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Direction not reportedTβ4 as a discriminative m/z species of preneoplastic lesions
    Study

    mousen: not reported in source

    genetically engineered mouse models of pancreatic cancer
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Among these m/z-species, we identified Albumin and Thymosin-beta 4 by liquid chromatography and tandem mass spectrometry (LC-MS/MS)
    2 context sentences
    Summary · context
    Intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) could be distinguished from normal pancreatic tissue and PDAC by 26 significant m/z-species.
    Summary · context
    To address this task we used the novel technique of matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) on genetically engineered mouse models (GEM) of pancreatic cancer.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    In mice with PanIN lesions, serum Tβ4 was significantly increased.

    In plain wordsIn mice with early pancreatic lesions, the body's own thymosin β4 in blood was higher.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseSerum Tβ4 in mice with PanIN lesions
    Study

    mousen: not reported in source

    genetically engineered mouse models of pancreatic cancer
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Thymosin-beta 4 was found significantly increased in sera of mice with PanIN lesions.
    1 context sentence
    Summary · context
    To address this task we used the novel technique of matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) on genetically engineered mouse models (GEM) of pancreatic cancer.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.